Advertisement
Advertisement
ELVN
Enliven Therapeutics Inc
21.47
USD-0.52
-2.37%
Jan 17, 15:58 UTC -5
Closed
...
Enliven Therapeutics Inc Profile
About
Info & Links
CEO
Samuel Kintz
Headquarters
Boulder, CO 80301, UNITED STATES
Industry
Sector
Website
Auditor
Deloitte & Touche LLP
Share holders
24
Employees
46
Enliven Therapeutics Inc Statistics
Valuation Measures
Market Capitalization2
1.05B
Enterprise Value
948.35M
Enterprise Value/EBITDA(ttm)
-9.26
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
3.56
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-29.46%
Return on Invested Capital(ttm)
-29.61%
Return on Assets(ttm)
-27.33%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-102.41M
Net Income Available to Common(ttm)
-85.21M
Diluted EPS(ttm)
-1.90
Share Statistics
Beta (5Y Monthly)
1.04
52-Week Change
86.70%
S&P 500 52-Week Change
25.43%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
48.86M
Dividend Yield
0.00%
Float4
34.59M
% Held by Insiders
29.20%
% Held by Institutions
95.08%
Balance Sheet
Total Cash(mrq)
291.89M
Total Cash Per Share(mrq)
5.97
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
17.44%
Quick Ratio(mrq)
17.44%
Book Value Per Share(mrq)
6.10
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.16
Free Cash Flow(ytd)
-56.03M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement